Bradenton, FLORIDA3 Active Studies

Ankylosing Spondylitis Clinical Trials in Bradenton, FLORIDA

Find 3 actively recruiting ankylosing spondylitis clinical trials in Bradenton, FLORIDA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
392
Enrolling

Recruiting Ankylosing Spondylitis Studies in Bradenton

About Ankylosing Spondylitis Clinical Trials in Bradenton

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 3 ankylosing spondylitis clinical trials recruiting participants in Bradenton, FLORIDA. These studies are seeking a combined 392 participants. Research is being sponsored by Connect Biopharm LLC, Pacira Pharmaceuticals, Inc, Altimmune, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Bradenton — FAQ

Are there ankylosing spondylitis clinical trials in Bradenton?

Yes, there are 3 ankylosing spondylitis clinical trials currently recruiting in Bradenton, FLORIDA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Bradenton?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Bradenton research site will contact you about next steps.

Are clinical trials in Bradenton free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Bradenton studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 3 active trials in Bradenton are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated March 2, 2026 from ClinicalTrials.gov